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Abstract
Background: Bacteria from the Burkholderia cepacia complex (Bcc) are the only group of cystic fibrosis (CF) respiratory
pathogens that may cause death by an invasive infection known as cepacia syndrome. Their large genome (> 7000 genes) and
multiple pathways encoding the same putative functions make virulence factor identification difficult in these bacteria.
Methods: A novel microarray was designed to the genome of Burkholderia cenocepacia J2315 and transcriptomics used to
identify genes that were differentially regulated when the pathogen was grown in a CF sputum-based infection model. Sputum
samples from CF individuals infected with the same B. cenocepacia strain as genome isolate were used, hence, other than a
dilution into a minimal growth medium (used as the control condition), no further treatment of the sputum was carried out.
Results:  A total of 723 coding sequences were significantly altered, with 287 upregulated and 436 downregulated; the
microarray-observed expression was validated by quantitative PCR on five selected genes. B. cenocepacia genes with putative
functions in antimicrobial resistance, iron uptake, protection against reactive oxygen and nitrogen species, secretion and motility
were among the most altered in sputum. Novel upregulated genes included: a transmembrane ferric reductase (BCAL0270)
implicated in iron metabolism, a novel protease (BCAL0849) that may play a role in host tissue destruction, an organic
hydroperoxide resistance gene (BCAM2753), an oxidoreductase (BCAL1107) and a nitrite/sulfite reductase (BCAM1676) that
may play roles in resistance to the host defenses. The assumptions of growth under iron-depletion and oxidative stress
formulated from the microarray data were tested and confirmed by independent growth of B. cenocepacia under each respective
environmental condition.
Conclusion: Overall, our first full transcriptomic analysis of B. cenocepacia demonstrated the pathogen alters expression of over
10% of the 7176 genes within its genome when it grows in CF sputum. Novel genetic pathways involved in responses to
antimicrobial resistance, oxidative stress, and iron metabolism were revealed by the microarray analysis. Virulence factors such
as the cable pilus and Cenocepacia Pathogenicity Island were unaltered in expression. However, B. cenocepacia sustained or
increased expression of motility-associated genes in sputum, maintaining a potentially invasive phenotype associated with cepacia
syndrome.
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Background
Cystic fibrosis (CF) is the most common hereditary dis-
ease in Caucasian population affecting one in every 2,500
– 4,500 newborns. People with CF lack a functional chlo-
ride transporter normally present in epithelial cell mem-
branes which results in multiple organ system
impairment. The respiratory tract is one of the most pro-
foundly affected systems where the defect in ion transport
causes production of highly viscous mucus. The resulting
ineffective mucocilliary clearance in the lung leads to col-
onization of the airway with several bacterial pathogens
and ultimately it is respiratory infections that are the
major cause of morbidity and mortality in individuals
with CF. The most problematic bacterial infections are
caused by Pseudomonas aeruginosa and the Burkholderia
cepacia  complex (Bcc), and are characterized by low
responsiveness to antibiotic therapy and significant reduc-
tions in a patient's lung function. Both bacteria also pose
the risk of epidemic spread within the CF community
[1,2], with the Bcc being distributed among CF patients to
much smaller extent (3 – 30%; [3] compared to P. aerugi-
nosa 70 – 80%; [1]). However, the clinical relevance of Bcc
infection is underlined by the fact that it is the only
known CF pathogen which can enter the blood circula-
tion and lead to fulminating septicaemia with acute respi-
ratory failure called "cepacia syndrome" [2]. The Bcc
represents a broad collection of closely related bacterial
species, of which Burkholderia cenocepacia and Burkholderia
multivorans are the most dominant species in CF infection
[1].
Although rapid clinical decline and epidemic spread is
linked to infection with a number of Bcc species, B. ceno-
cepacia is regarded as one of the most virulent and prob-
lematic CF pathogens [2]. This species accounts for 50 –
90% of all Bcc infections diagnosed in CF patients in dif-
ferent national CF centres [1,4] and includes strains with
a well documented history of patient-to-patient transmis-
sion, as well as strains exhibiting a high virulence poten-
tial [5,6]. Several epidemic B. cenocepacia strains have
been described [7]. One strain type, known as ET12, was
one of the first highly transmissible strains to be described
and caused multiple infection outbreaks in Canada and
the United Kingdom that were associated with significant
mortality among CF patients [8]. As a result of its clinical
significance, the ET12 B. cenocepacia strain J2315 [7] was
the first Bcc pathogen selected for genome sequence deter-
mination at the Wellcome Trust Sanger Institute. The
complete J2315 genome subsequently became the basis
for developing the first custom microarray of a B. cenoce-
pacia species [9,10].
A number of pathogenic traits have been identified in B.
cenocepacia including lipopolysaccharide, various adhes-
ins, flagella, siderophores, type III secretion system, quo-
rum sensing, genomic islands, haemolysins, extracellular
proteases, exopolysaccharide, resistance to antibiotics and
to reactive oxygen species, and the ability to form biofilms
(reviewed in [2]). Despite this extensive research, the indi-
vidual contribution of each virulence determinant and
their potential interaction with other virulence factors
during CF infection has not been extensively addressed. In
addition, Burkholderia genomes are among the largest in
bacteria ranging from 6 Mb to greater 9 Mb [11]. Their
genomes also contain multiple pathways for related func-
tions and considerable gene redundancy due to presence
of paralogous genes [12]. Hence, pin-pointing which
genes are active in specific environments is not straightfor-
ward due to the large number of predicted functional
redundancies in their genomes.
In order to characterize the molecular processes that take
place in B. cenocepacia at an early stage of infection, we
studied the global gene expression changes that occur dur-
ing growth in CF sputum modelled under laboratory con-
ditions. By using a genomic microarray approach, we were
also able to profile expression and uncover which of the
many paralogous gene systems in B. cenocepacia are active
in an environment mimicking infection. Examining gene
expression in sputum-based models has only been per-
formed with P. aeruginosa, using UV-irradiated CF sputum
[13] or artificial sputum [14]. In this first complete study
of B. cenocepacia sputum-transcriptomics, we were able to
work with CF sputum samples in a non-sterilized, close to
native form since the CF individuals examined were
chronically infected with ET12 strains that were deter-
mined by microbial reference centres using standard pro-
cedures [1,2] to be genetically identical to our
experimental strain J2315. The transcriptome of a B. ceno-
cepacia population resulting directly from the pathogen-
host interaction in sputum from three CF individuals was
measured using multiple biological replicates. A complex
picture of the pathophysiological state of B. cenocepacia
during an early stage of infection was developed by inter-
preting the expression levels of individual genes that were
specifically activated or suppressed in the CF sputum envi-
ronment. Pathogenic traits that were altered in this model
of growth during respiratory infection included activation
of protective mechanisms against antibiotics and reactive
oxygen species, a response to balance changes in concen-
tration of internal iron, and upregulation of two well
known virulence factors, flagella and metalloproteases.
Methods
Microarray
A custom 2 × 11 K microarray for B. cenocepacia was devel-
oped using Agilent's two colour 60-mer ink jet synthesis
platform (Agilent Technologies, Santa Clara, California).
A partial genomic microarray and labelling procedures
using this technology had already been validated [10].BMC Infectious Diseases 2008, 8:121 http://www.biomedcentral.com/1471-2334/8/121
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The microarray was composed of 10,807 probes which
were specific to the following features; annotated J2315
CDS (a total 7,251 probes including duplicate probes for
several genes), selected J2315 intergenic regions (1,489),
probes for CDS specific to other two sequenced B. cenoce-
pacia  strains AU1054 and HI2424 (1,457), and 610
probes serving as technical controls (the array definition
file is deposited in ArrayExpress under the accession
number A-MEXP-867). The genome sequence of B. ceno-
cepacia strain J2315 was produced by the Pathogen
Sequencing Group at the Sanger Institute, Hinxton, Cam-
bridge http://www.sanger.ac.uk/Projects/B_cenocepacia,
and the sequences of strains AU1054 and HI2424 were
produced by the produced by the US Department of
Energy Joint Genome Institute http://www.jgi.doe.gov.
Sputum samples
The respiratory samples were obtained from adult CF
patients as routine diagnostic specimens sent for micro-
biological analysis. For each patient the clinical condition,
bacterial infection and antibiotics administered have been
summarised in Table 1. Sputa from three CF patients
infected with the ET12 B. cenocepacia were used in the
microarray based analysis: patient 1 and patient 2 were
clinically stable at the time of sampling (sputum 1 and 2),
while patient 3 was suffering an exacerbation (sputum 3;
Table 1). Subsequently, along with sputum 2 and 3, three
additional sputum samples from three further CF patients
were examined using quantitative PCR to validate the
microarray observed gene expression: patient 4 (sputum
4) was infected with B. cenocepacia and clinically stable;
patient 5 (sputum 5) was infected only with P. aeruginosa
and exacerbating, and patient 6 (sputum 6) was also only
infected with P. aeruginosa but stable at the time the sam-
ple was provided (Table 1).
Each sputum sample was stored frozen in its native form
at -20°C and upon arrival to the research laboratory, they
were thawed, diluted in a minimal basal salts medium
(BSM) containing 14.3 mM glucose and 0.05% casamino
acids [15] to a concentration of 12.5% w/vol, homoge-
nized by passage through a 10 ml syringe 20 × and
archived at -20°C. The total iron concentration of the spu-
tum samples and basal salts media was determined using
standard atomic adsorption spectrometry at 248.3 nm in
an air acetylene flame (Varian SpectrAA-100 running
Spectra-100 Version 2 Software). A standard curve was
prepared using a spectrosol iron standard (VWR Scientific,
UK).
Growth conditions
All incubations were carried out at 37°C with shaking in
an orbital shaker set at 220 rpm. A 3 ml starter culture of
J2315 (harvested at mid-log growth phase growth in
Luria-Bertani broth; OD600 nm 0.5) was split into two aliq-
uots and centrifuged (8 minutes, 650 × g). The pellet was
resuspended in 3 ml BSM and 1 ml (~1 × 108 colony form-
ing units; cfu) inoculated into either: (i) 4 ml BSM (con-
trol) or, (ii) 4 ml BSM supplemented with homogenized
CF sputum at 12.5% w/vol, giving a final sputum concen-
traton of 10% w/vol in the 5 ml culture volume (test).
Incubation was continued until the culture optical density
had increased by OD600 nm 0.6 (an equal increase in cul-
ture density rather than an equal time period of incuba-
tion). For each experiment this meant that growth started
at an OD600 nm of between 0.3 and 0.4 and was then har-
vested at an OD600 nm of between 0.9 and 1.0, providing
sufficient time for B. cenocepacia to adapt is gene expres-
sion to the new growth condition. After growth, the cul-
tures were then immediately cooled in liquid nitrogen
and briefly centrifuged (1 minute, 160 × g, 4°C) to
remove heavy particulate matter. To lyse human cells and
enable better purification of bacteria specific RNA, the
supernatants were mixed with an equal volume of 0.2%
Triton X-100 in BSM, left for 10 minutes on ice, diluted
with 5 volumes of BSM and centrifuged to collect the bac-
teria (5 minutes, 5,000 × g, 4°C). The resulting pellets
were snap frozen in liquid nitrogen and stored at -80°C.
RNA extraction, labelling and hybridization
Total RNA was isolated using RNeasy Mini Kit (Qiagen)
according to the manufacturer's instructions including the
optional step of homogenization with a QIAshredder spin
columns. To increase RNA yield, we performed an addi-
tional sonication step at the beginning of RNA isolation
(10 × 10 second pulses, each at 5 μm amplitude, with a
Sanyo Soniprep 150 Watt sonicator). After the extraction,
the RNA was concentrated by using 7.5 M Lithium Chlo-
ride (Ambion). Between 4.5 – 15 μg of RNA was used to
synthesize and form labelled cDNA with the CyScribe
Table 1: Sputum samples examined
Patient (sputum) number: Patient's clinical status: Infection: Antibiotic treatment:
1 Clinically stable B. cenocepacia azithromycin, flucloxacillin, aztreonam, tobramycin
2 Clinically stable B. cenocepacia azithromycin, minocycline
3 Pulmonary exacerbation B. cenocepacia azithromycin, ceftazidime, gentamicin
4 Clinically stable B. cenocepacia azithromycin, flucloxacillin
5 Pulmonary exacerbation P. aeruginosa meropenem, tobramycin
6 Clinically stable P. aeruginosa ciprofloxacin, tobramycinBMC Infectious Diseases 2008, 8:121 http://www.biomedcentral.com/1471-2334/8/121
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Post-Labelling Kit (an indirect amino-allyl procedure) fol-
lowing the manufacturer's instructions (Amersham). The
fluorescent signal of each labelled sample was checked by
electrophoretic separation of 1 μl of sample in a mini-aga-
rose gel followed by scanning (GeneTAC GTLS IV Scanner,
Genomic Solutions Inc.). Equal intensities of Cy3- and
Cy5-labelled cDNA (approximately 0.5 μg of each) were
combined and left to hybridize to the microarray at 65°C
for 17 hours. The microarray slides were washed accord-
ing the manufacturer's instructions (Agilent's microarray
processing protocol) with initial washes in the solutions
containing two different concentrations of SSPE and N-
lauroylsarcosine, and a final wash in the Stabilization and
Drying Solution. Signal intensities were scanned with the
DNA Microarray Scanner (Agilent) and processed with the
Feature Extraction v8.1 software (Agilent).
Microarray experimental design and analysis
For each patient's sputum, growth and RNA extraction
was performed as two independent technical replicates.
Each technical replicate comprised a direct comparison of
paired Cy3-labelled control (growth in BSM) and Cy5-
labelled test (growth in sputum) conditions. Biological
replicates were generated by combining analysis of the
three CF patients' samples. In addition, a self-hybridiza-
tion control experiment was performed to evaluate and
overcome potential gene-specific dye bias. cDNA from all
the control samples, in both Cy3- and Cy5-linked forms,
were combined and hybridized on two replicate microar-
rays. The experimental protocols and raw microarray data
can be found in ArrayExpress under the accession number
E-MEXP-1261.
Gene expression data analysis was performed using Gene-
Spring GX 7.3 (Agilent) and only features dedicated to
J2315 (i.e., 7,251 CDS and 1,489 intergenic regions) were
included in the analysis. Microarray data was examined in
two ways. Initially, the three patient-specific biological
replicates were each tested using Student's one-sample t-
test and their changes in gene expression were defined by
fold change relative to the gene expression level in self-
hybridization assay; this analysis was performed with a
two-fold change filter applied and no multiple testing cor-
rection or statistical significance filter of p < 0.05 adopted.
The second analysis involved applying the same statistical
testing to the original, unmodified combined dataset of
six technical replicates in order to identify reproducible
trends that result from growth of B. cenocepacia in sputum.
This analysis was performed with the false discovery rate
algorithm applied and a statistical filter of p < 0.05
adopted.
Quantitative PCR
In order to validate microarray results, five genes with
identified altered expression in sputum (4 overexpressed:
BCAL0270, BCAM2753, BCAL1107 and BCAM1676; and
1 underexpressed: BCAL1165) were examined individu-
ally by using either semi-quantitative reverse transcriptase
PCR (RT-PCR) or Real Time PCR (RQ-PCR) approaches.
PCR primers targeting the test genes are shown in Table 2.
The gene phaC (BCAL1861), with constant expression in
both control and test microarrays, was used as a control
for all quantitative PCR work and amplified using previ-
ously described primers [16]; Table 2). Irrespective of
growth condition, BCAL1861 possessed a raw fluorescent
microarray signal lying above the 75th percentile of all
genes with unaltered expression (fold change 0.667–
1.334; among approximately 2,500 genes). This also dem-
onstrated that the BCAL1861 transcript was highly abun-
dant in all growth conditions. The semi-quantitative
Table 2: PCR primers and conditions for quantitative PCR
Gene Forward and reverse primer (5' – 3') Product size (bp) Tm (°C)
Real-time PCR
Control gene BCAL1861 (phaC) AGACGGCTTCAAGGTGGT
ACACGGTGTTGACCGTCA
470 62/66
BCAL0270 GCGCGAACCCGATCGAATTC
GCCCGCATCCACCAGAAGTG
400 66
BCAM2753 GAACCGCAGACGCTGTACTC
AAACGCTCGGTGTTGCGGAC
380 62
BCAL1107 GAATCGACGTATCGGCTCGT
ATGATGTGCTTCGGGTTCTTG
377 66
BCAM1676 GACGACCTGTTCCTGCTGTG
CGGCTCTTCCTGATGACGTG
534 62
Semi-quantitative PCR
BCAL1165 TGACGCTCGGCACCGTTGAC
GCGTGGACCTGCTCGATCTC
400 66BMC Infectious Diseases 2008, 8:121 http://www.biomedcentral.com/1471-2334/8/121
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method was based on the endpoint analysis of ordinary
PCR reactions varying in their number of cycles as
described elsewhere [9].
More accurate levels of gene expression fold change were
obtained from the RQ-PCR analysis where delta delta CT
or Pfaffl methods [17] were applied. The primers and
gene-specific annealing temperature for PCR conditions
are provided in Table 2; each PCR reaction for semi-quan-
titative RT-PCR contained 0.2 mM (each) dNTPs, 2 mM
MgCl2, 0.5 μM (each) primer and 0.75 U of GoTaq
polymerase (Promega, Madison, USA), while ABsolute
SYBR Green Mix (Abgene, Epsom, United Kingdom) with
MgCl2 concentration of 3 mM was used for the RQ-PCR.
The amplifications were run on a MJ Research PTC-200
thermal cycler with the option of real-time fluorescence
detection (DNA Engine Opticon). The thermal cycling
profile consisted of 15 sec at 95°C, 30 sec at annealing
temperature (dependent on the gene being analyzed, see
Table 2) and 15 sec at 72°C. Furthermore, the RQ-PCR
profile included an initial 15-minute incubation at 95°C
required for hot start PCR and a melting curve analysis at
the end of PCR.
A template for semi-quantitative PCR was prepared by
pooling the same RNAs (representing either growth in
sputum or growth in BSM) used previously for microar-
rays. In addition, we generated five more RNAs from addi-
tional growth experiments with five other sputum
samples (carried out in accordance with the protocol for
growth of J2315 in sputum) and four other RNAs which
had represented a response of J2315 to following condi-
tions: (i) low iron concentration (no FeSO4  in BSM
growth medium), (ii) presence of 0.1% H2O2 in BSM; (iii)
presence of 0.15% H2O2; and (iv) presence of t-butyl
hydroperoxide (0.002% in BSM). Extracted RNA was con-
verted in the amount of 0.1 μg into cDNA by using
Improm-II Reverse Transcription System (Promega) and
500 ng of cDNA was added into each PCR reaction. To cal-
culate fold change in expression when RQ-PCR method
was used, every run comprised cDNAs from test (growth
in sputum or other test condition) as well as from control
(growth in BSM) where their gene of interest and their ref-
erence housekeeping gene phaC [16] were examined each
in triplicate. The efficiency of PCR for both genes was
determined by serial dilutions of control cDNA over the
range of two orders of magnitude.
Results
Extraction of B. cenocepacia RNA from sputum and 
microarray performance
Initial attempts to extract RNA from bacteria grown in
sputum were inconsistent due to components of sputum
interfering with the procedure. Therefore a washing proce-
dure was developed which diluted the sputum in a Triton
X100 containing buffer (to lyse human cells), gently cen-
trifuged it to remove large particles, and finally forcefully
centrifuged to collect bacteria (see Methods and Materi-
als). Once the RNA extraction procedure had been opti-
mised, the transcriptomic profiles of B. cenocepacia
obtained were excellent. The array-to-array correlation
within a technical duplicate from a single patient's spu-
tum pair ranged from 0.965 to 0.985; variation across all
3 patients ranged from 0.894 to 0.956. These high-corre-
lation coefficients indicated that the custom microarrays
provided good quality technical performance over the
entire microarray experiment. More importantly, the >
89% similarity between biological replicates demon-
strated that there was a high degree of relatedness between
sputum samples resulting in a rigorous biological dataset
that could be mined for gene expression changes. More
than 97% (8,533) of J2315-specific features presented on
the microarray were eligible for gene expression analysis
as they were consistently above the background noise
defined by the scanner detection calls.
Microarray data analysis
Microarray data was examined in two ways as described in
Materials and Methods. The analysis based on the three
biological replicates demonstrated that 182 genetic fea-
tures were significantly over-expressed while 296 were
down-regulated with the two fold filter applied. The alter-
native analysis of the entire dataset where the six arrays
were handled as six independent entities revealed 950
genetic features to be significantly altered in expression,
with 411 up-regulated and 539 down-regulated. A total of
454 genes overlapped both analytical approaches and
only 24 genes (1 up- and 23 downregulated) from the
three biological replicate-based analysis were not present
in the larger dataset from six technical replicates. Since
both analyses demonstrated excellent concordance the
results were combined, adding the 24 genes from the bio-
logical replicate analysis to the 950 genetic features from
the six replicates, allowing 974 genetic elements (coding
sequences [CDSs], rRNA, tRNA and intergenic regions)
with 2 fold or greater alteration in expression to be evalu-
ated (see Additional Files 1 and 2 for complete lists of up-
and downregulated genes respectively). The low, 2-fold,
threshold for a change in gene expression was selected to
minimize the risk of missing false negative results. For
example, multidrug efflux pump protein genes may dem-
onstrate expression changes as low as 1.3 fold, yet such a
minor change is known to dramatically alter the physio-
logical activity of the pump [18].
Based on the parameters defined above, B. cenocepacia
growth in sputum compared to growth in minimal salts
medium altered the expression of 723 CDSs representing
10% of all CDSs annotated to date in the genome of J2315
(a total of 7,176). Of these CDSs, 287 were upregulatedBMC Infectious Diseases 2008, 8:121 http://www.biomedcentral.com/1471-2334/8/121
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(see Additional File 1) and 436 downregulated (see Addi-
tional File 2). In addition, 33 tRNAs, 2 rRNAs and 2 small
RNAs were found over-expressed (Additional File 1). The
upregulation of tRNAs may have resulted as a direct con-
sequence of B. cenocepacia growth in sputum-enriched
BSM which effectively made it a nutrient-rich medium.
Interestingly, approximately one quarter (24.2%) of the
differentially expressed genes were unique to strain J2315
in comparison to the complete genomes of other B. ceno-
cepacia strains (AU1054 and HI2424); specifically 29% of
the upregulated CDSs and 21% of the downregulated
CDSs were unique to J2315. Also, around 10% of these
unique CDSs were found in indel regions rather than in
genomic islands region (11.8% of upregulated and 8.0%
of downregulated). Although 18% (130/723) of the CDSs
with altered expression lacked functional descriptions, the
remaining CDSs differentially expressed in the presence of
sputum were composed of several functional groups.
Major classes of B. cenocepacia genes with altered expres-
sion in sputum were selected from the microarray dataset
for further discussion and analysis, including genes play-
ing a role in virulence, antimicrobial resistance, iron
uptake, protection against reactive oxygen species (ROS)
and nitrogen species, bacterial attachment, motility and
secretion.
Validation of microarray expression data
We confirmed the microarray data by both semi-quantita-
tive reverse transcriptase PCR and Real-Time PCR (RQ-
PCR) designed to target five genes with altered expression
and one control gene of constant expression (Table 2 and
3). The target genes selected were representative of: (i) a
range of observed changes in expression (from 6- to 66-
fold), and (ii) different functional classes of genes with
altered expression (Table 3). Semi-quantitative PCR was
initially applied to BCAL0270, encoding a putative ferric
reductase transmembrane protein (36 × upregulated), and
BCAL1165, a conserved hypothetical gene (6 × downreg-
ulated; RQ-PCR analysis of this gene was not possible due
to limited sensitivity). Using pooled cDNA from the
microarray experiments, in the sputum growth condition
BCAL0270 was consistently amplified after 5 fewer cycles
in comparison to the phaC (BCAL1861) house-keeping
control gene while in contrast, BCAL1165 was not ampli-
fied until 35 cycles in comparison to the control gene
BCAL1861 (Figure 1); this corroborated the microarray
data showing that BCAL0270 was upregulated and
BCAL1165 downregulated in sputum. During growth in
BSM signals for BCAL270, BCAL1165 and the control
phaC gene all appeared after 30 cycles (Figure 1) indicat-
ing similar levels of relative expression for all these genes
in this growth condition. Although a signal for the control
gene was absent in sputum yet present in BSM at 30 cycles
of amplification (Figure 1), this probably resulted from
Table 3: Confirmation of B. cenocepacia gene expression by Real Time PCR
Real-time PCR fold change using delta delta CT method
Gene expression determined from 
(infection; clinical condition):
BCAL0270
(ferric reductase 
transmembrane component)
BCAM2753
(ohr gene, organic 
hydroperoxide resistance protein)
BCAL1107
(oxidoreductase)
BCAM1676
(nitrite/sulfite 
reductase)
Microarray dataset
(Sputum 1, 2, and 3; see below)
↑ 36 ↑ 8 ↑ 66 ↑ 20
Sputum 2
(B. cenocepacia; stable)
↑ 160 ↑ 100 ↑ 914 ↑ 97
Sputum 3
(B. cenocepacia; exacerbation)
↑ 65 ↑ 40 ↑ 299 ↑ 4
Sputum 4
(B. cenocepacia; stable)
↑ 25 ↑ 22 ↑ 235 -
Sputum 5
(P. aeruginosa; exacerbation)
↑ 22 ↑ 71 ↑ 189 -
Sputum 6
(P. aeruginosa; stable)
↑ 3 ↑ 3 ↑ 12 ↑ 94
Average for sputum growth ↑ 55 ↑ 47 ↑ 330 ↑ 65
Fold change in minimal media with:
No FeSO4 ↑ 2-
0.1% H2O2 - ↑ 5
0.15% H2O2 - ↑ 3
0.002% t-butyl hydroperoxide - ↑ 2BMC Infectious Diseases 2008, 8:121 http://www.biomedcentral.com/1471-2334/8/121
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less cDNA template being present in the sputum-recov-
ered samples, as the microarray-observed gene expression
had shown that the phaC  control gene was stable in
expression relative to all other genes for both sputum and
BSM growth.
In addition to examining the cDNA used in the microarray
analysis, RQ-PCR was then applied to fresh RNA extracted
from B. cenocepacia J2315 grown in additional aliquots of
sputum samples 2 and 3 that had been used for the micro-
array analysis, as well as samples from three additional CF
patients (Table 3). This set of RNAs allowed gene expres-
sion to be tested in multiple population replicates,
accounted for biological variability between samples, and
enabled the calculation of mean values of gene alteration
that were more representative of CF infection conditions.
Expression analysis by RQ-PCR of four selected upregu-
lated genes correlated well with the results observed by
microarray analysis (Table 3).
Quantitative PCR demonstrated that each gene was con-
sistently upregulated after B. cenocepacia growth in all five
different sputum samples (Table 3). However, the fold
change of expression varied considerably, with the most
extreme case being the putative oxidoreductase encoding
gene (BCAL1107) whose mean fold change across the five
sputum samples was 5 times greater than had been
observed for the three sputum samples examined using
the microarrays (Table 3). Although the differences in
upregulation were substantial, all were similar to or above
that seen in the microarray analysis except for expression
of BCAL0270, BCAM2753, and BCAL1107 observed after
B. cenocepacia growth in sputum 6 (Table 3). Each of the
latter genes were still upregulated in sputum 6 compared
to the control, however, the values were 12, 2.5 and 5.5
less, respectively, than those measured from the microar-
ray dataset.
The excellent correlation between the microarray data and
RQ-PCR demonstrated that the B. cenocepacia custom
microarray was performing very well and also illustrated
the importance of using of the three biological replicates
(3 CF individuals) to provide an unbiased set of sputum-
growth microarray data. RQ-PCR data related to two
selected genes (BCAL0270 and BCAM2753) will be dis-
cussed further in the relevant sections describing the func-
tional classes of genes with altered expression during B.
cenocepacia growth in sputum.
B. cenocepacia antimicrobial resistance
CF patients are typically treated with a combination of
antibiotics including beta-lactams, macrolides, tetracy-
clines, aminoglycosides and polymyxins. At the time of
sputum collection each patient was receiving antibiotics
as follows: patient 1 was on long-term flucloxacillin and
azithromycin and had just started a course aztreonam and
tobramycin at the time the specimen was provided;
patient 2 was receiving a course of azithromycin and
minocycline, while patient 3 was on long-term azithromy-
cin therapy with the additional prescription of ceftazi-
dime, fluconazole and gentamicin. Hence the
identification of antibiotic resistance genes with altered
expression was expected due to traces of antibiotics being
present in the sputum samples as a result of daily therapy.
Antibiotic efflux is known to be a primary resistance
mechanism in Bcc bacteria [2]. After growth of B. cenoce-
pacia in sputum, we detected gene expression changes in
three of the multiple resistance-nodulation-cell division
(RND) efflux operons [19]: BCAL1675 and BCAM1947
were upregulated while BCAL1813 was downregulated
(Table 4). The ceo operon is arguably the most well char-
acterised RND pump encoding cluster in B. cenocepacia
(corresponding to genes BCAM2549-2552, 2554) [20].
We did not detect any expression changes in genes from
the ceo cluster, correlating to a lack of chloramphenicol,
trimethoprim or ciprofloxacin therapy in the patients
examined. Significantly altered expression was also found
in five more efflux transporter systems which did not
Validation of microarray observed B. cenocepacia gene  expression by semi-quantitative PCR Figure 1
Validation of microarray observed B. cenocepacia 
gene expression by semi-quantitative PCR. The results 
of semi-quantitative RT-PCR on cDNA derived from spu-
tum-grown B. cenocepacia (panel A) and from cells grown 
under control conditions (panel B) are shown. The products 
amplified after set numbers of PCR cycles (labelled below 
each panel) are shown for the following genes: 1, ferric 
reductase transmembrane gene (BCAL0270; up-regulated in 
sputum); 2, conserved hypothetical gene (BCAL1165; down-
regulated in sputum); and 3, phaC (BCAL1861; control gene 
without altered expression). Molecular size markers are 
shown on the left hand side of each gel and the relevant size 
fragments indicated in bp.BMC Infectious Diseases 2008, 8:121 http://www.biomedcentral.com/1471-2334/8/121
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belong to RND family (upregulated pumps were:
BCAM0200, BCAM0791/792; downregulated pumps
were BCAL1510, BCAL3511/514 and BCAS0015; Table
4).
Enzymatic inactivation is another mechanism of antibi-
otic resistance that is intrinsic to B. cenocepacia especially
with regard to chromosomally encoded betalactamases
[2]. However, none of the 4 annotated betalactamases
(BCAM0393, BCAM1179, BCAM2165 and BCAS0156) in
the genome were altered in expression, however, a 20-fold
change in BCAS0034 was observed. This chromosome 3
encoded gene possesses a conserved metallo-betalacta-
mase domain but whether the encoded protein may act as
functional betalactamase remains to be determined. The
potential effects of beta-lactam compounds being present
in the sputum examined was also indicated by expression
changes observed in genes encoding penicillin binding
proteins, of which BCAL0704 and BCAL2832 were down-
regulated, while BCAM1362 was upregulated (Table 4).
Iron uptake and metabolism
Iron is an essential element required by microorganisms
for many biological processes, yet its supply in a form of
free, non-bound iron, is limited in the host environment.
Pathogenic bacteria have evolved various iron acquisition
mechanisms for the utilization of extracellular iron
sources, with siderophore secretion and uptake being one
of the most effective systems. B. cenocepacia produces sev-
eral types of siderophore including ornibactin, pyochelin
and salicylate, although the salicylate might function as a
pyochelin precursor rather than a siderophore per se [21].
During the growth in sputum B. cenocepacia activated two
genes involved in biosynthesis of salicylate/pyochelin
(pchR; BCAM2231 and pchD; BCAM2232) and suppressed
the expression of a transcriptional repressor Fur, the glo-
bal iron regulator (BCAL2812). Interestingly, the gene
cluster encoding biosynthesis of another B. cenocepacia
siderophore, ornibactin (BCAL1688-1702), was not acti-
vated during sputum growth; this siderophore has, how-
ever, been shown to be important for the pathogenesis in
rat model of chronic lung infection [22]. The increased
demand of the bacterium for iron was also reflected by
immense over-expression (> 35×) of a membrane ferric
reductase (BCAL0270) which catalyzes reduction of
siderophore-bound ferric ions to soluble ferrous ions.
The Tol system in P. aeruginosa is also known to mediate
transport of iron-containing siderophores into bacterial
cells and under iron-restricted conditions at the late log
stage of growth, the P. aeruginosa tol genes are known to be
downregulated [23]. Three B. cenocepacia genes homolo-
gous to the tol system (BCAL3201, BCAL3203-3204) were
found to be downregulated in sputum suggesting that the
growth environment was iron-restricted. Once in cyto-
plasm, iron can be sequestered in storage proteins such as
bacterioferritin or iron-sulphur proteins. We detected sig-
nificantly higher expression of cyaY gene (BCAL0273, 8
fold upregulation; Table 4) which is a bacterial ortholog
of a protein frataxin, an iron donor for assembly of Fe-S
clusters in eukaryotes [24].
Although the infected CF lung has traditionally been con-
sidered an iron-deficient environment, this dogma has
been the subject of considerable research and debate [25].
The significant expression changes in B. cenocepacia genes
involved in the iron cycle implied that the sputum-based
growth model we examined represented an iron-depleted
condition. The overall iron concentration in CF sputum,
approximately 3 × 10 -5 M [26] is high from a bacterial
growth standpoint. The total iron concentration in our
10% mixtures of sputum 2 and 3, was 3.6 × 10-5 M (1.98
ppm) and 3.5 × 10-5 M (1.96 ppm), respectively, and was
comparable to the control basal salts medium at 3.7 × 10-
5 M (2.1 ppm). However, the total iron measured in spu-
tum is composed of both ionic forms, of which only the
soluble ferrous ions can be readily utilized by bacteria
without using siderophores. Hence, in our experimental
model the ferrous form of iron was likely to have been
lower in the 10% sputum medium, than in the control
BSM which contained solely soluble ferrous ions. The
microarray data and RQ-PCR results on additional spu-
tum samples had shown substantial up-regulation of a
ferric reductase membrane protein gene (BCAL0270),
ranging from 3 to 160 fold increases (Table 3), suggesting
that B. cenocepacia gene expression was being altered due
to iron limitation. To mimic the assumed iron-depleted
condition and evaluate its linkage to the iron-regulated
gene expression, B. cenocepacia J2315 was grown in mini-
mal media BSM with no iron salts added (4.1 × 10-6 M
available iron; 0.2 ppm) and the expression of BCAL0270
quantitated as an iron marker gene. Growth of B. cenoce-
pacia in the low iron media resulted in a 2 fold up-regula-
tion of BCAL0270, corroborating the assumption that its
expression in sputum was being activated by a reduction
in iron concentration (Table 3).
Protection against reactive oxygen and nitrogen species
Bacteria possess multiple mechanisms to protect them-
selves from toxic reactive oxygen species such as hydrogen
peroxide, hydroxyl radicals, superoxide and organic
hydroperoxides. Bacterial respiration and metabolism is
an additional endogenous source of ROS and during
growth in sputum this metabolic reservoir appeared to
have increased leading to extreme up-regulation in two
oxidoreductases (BCAL0269, 20-fold; BCAL1107, 65-
fold; Additional File 1) and cytochrome b (BCAL1106; >
90 fold; Additional File 1). Since CF patients experience
chronic lung inflammation their sputum is also reservoir
of harmful ROS compounds. Although we expected that aBMC Infectious Diseases 2008, 8:121 http://www.biomedcentral.com/1471-2334/8/121
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Table 4: Major groups of B. cenocepacia genes with altered gene expression in sputum
Gene number: Fold change in expression Putative gene function:
Antimicrobial resistance
upregulated
BCAL1675 2.67 multidrug efflux system transporter protein AmrB
BCAM0200 2.20 efflux system transport protein
BCAM0791 2.11 Major Facilitator Superfamily protein
BCAM0792 2.45 efflux system transport protein
BCAM1362 2.06 putative penicillin-binding protein
BCAM1947 3.76 putative quinoxaline efflux system transport protein
BCAS0034 19.84 metallo-beta-lactamase superfamily protein
downregulated
BCAL0704 2.61 D-alanyl-D-alanine carboxypeptidase (penicillin-binding protein precursor)
BCAL1510 2.72 putative multidrug resistance transporter protein
BCAL1813 2.37 multidrug efflux system outer membrane protein
BCAL2832 2.07 D-alanyl-D-alanine carboxypeptidase/endopeptidase (penicillin-binding protein precursor)
BCAL3511 2.08 multidrug resistance transporter protein
BCAL3514 2.11 outer membrane efflux protein
BCAS0015 2.09 efflux system transport protein
Iron uptake & metabolism
upregulated
BCAL0270 35.59 ferric reductase-like transmembrane component
BCAL0273 8.23 protein CyaY
BCAM2231 2.86 transcriptional regulator PchR
BCAM2232 2.11 putative pyochelin biosynthetic protein PchD
downregulated
BCAL2812 2.59 putative Fur family transcriptional regulator
BCAL3201 2.59 putative TolR-related protein
BCAL3203 2.18 putative periplasmic TolB protein
BCAL3204 2.67 putative OmpA family lipoprotein
Protection against reactive oxygen and nitrogen species
upregulated
BCAL1766 2.23 OsmC-like protein
BCAM1676 19.99 putative nitrite/sulfite reductase
BCAM1677 26.75 conserved hypothetical protein
BCAM2753 8.00 putative organic hydroperoxide resistance protein, ohr gene
Downregulated (none)
Motility and adherence
upregulated
BCAL0124 2.02 flagellar regulon master regulator subunit FlhD
BCAL0525 2.17 flagellar M-ring protein FliF
BCAL0527 2.34 flagellar protein FliS
BCAL3506 2.58 flagellar motor switch protein FliM
BCAM0987 2.69 flagellar hook protein 2 FlgE2
BCAM2143 2.33 cable pilus associated adhesin protein
BCAS0299 3.55 flp type pilus subunit
downregulated
BCAL3504 3.31 flagellar protein FliO
BCAM2758 2.35 two-component regulatory system, sensor kinase protein
BCAM2759 3.73 putative minor pilin and initiator
BCAM2761 2.53 giant cable pilus
BCAM2762 2.81 giant cable pilus chaperone proteinBMC Infectious Diseases 2008, 8:121 http://www.biomedcentral.com/1471-2334/8/121
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BCAS0301 2.03 putative flp type pilus leader peptidase
Secretion
upregulated
BCAL0849 3.39 metallo peptidase, subfamily M48B
BCAL3517 2.36 type II secretion system protein L
BCAM2040 2.98 type III secretion system protein
BCAM2042 2.16 type III secretion system protein
BCAS0196 3.25 putative polygalacturonase
BCAS0409 6.36 zinc metalloprotease ZmpA
downregulated
BCAL3515 2.62 type II secretion system protein N
BCAL3521 3.19 type II secretion system protein I
BCAL3522 2.21 type II secretion system protein H
BCAM0240 2.47 N-acylhomoserine lactone dependent regulatory protein
Selected gene clusters
upregulated
BCAL0269 20.82 putative oxidoreductase
BCAL0270 35.59 ferric reductase-like transmembrane component
BCAL1106 90.32 cytochrome b561 family protein
BCAL1107 65.79 putative oxidoreductase
BCAL1153 3.30 putative salicylaldehyde/benzaldehyde dehydrogenase
BCAL1156 2.02 putative 4-hydroxybenzoate transporter
BCAL1157 2.51 putative monooxygenase
BCAM1676 19.99 putative nitrite/sulfite reductase
BCAM1677 26.75 conserved hypothetical protein
BCAM2749 31.39 carboxymuconolactone decarboxylase family protein
BCAM2750 14.06 putative exported protein
BCAM2751 7.13 LysR family regulatory protein
BCAM2752 12.35 NAD dependent epimerase/dehydratase family protein
BCAM2753 8.00 putative organic hydroperoxide resistance protein
BCAM2754 10.46 putative ketoreductase
downregulated
BCAL1130 2.10 conserved hypothetical protein
BCAL1161 2.46 conserved hypothetical protein
BCAL1162 2.30 TetR family regulatory protein
BCAL1165 5.59 conserved hypothetical protein
BCAL1166 4.07 conserved hypothetical protein
BCAL1168 3.06 conserved hypothetical protein
BCAL1169 2.05 conserved hypothetical protein (pseudogene)
BCAL3104 8.00 urease gamma subunit
BCAL3105 2.22 urease beta subunit
BCAL3106 2.34 urease alpha subunit
BCAL3109 2.42 urease accessory protein
BCAM0066 5.13 putative lipoprotein
BCAM0067 14.47 putative short chain dehydrogenase
BCAM0068 11.74 Major Facilitator Superfamily protein
BCAM0069 21.83 conserved hypothetical protein
BCAM0070 15.46 putative hydrolase
BCAM0071 11.11 puatative mandelate racemase lactonizing enzyme
BCAM0072 16.58 putative thiamine pyrophosphate enzyme
BCAM0073 6.85 hypothetical protein
BCAM0074 9.43 conserved hypothetical protein
Table 4: Major groups of B. cenocepacia genes with altered gene expression in sputum (Continued)BMC Infectious Diseases 2008, 8:121 http://www.biomedcentral.com/1471-2334/8/121
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large number of ROS defence mechanisms to be activated,
only two genes, both previously uncharaterized in B. cen-
ocepacia, were significantly upregulated during growth in
sputum. An 8-fold increase in expression of the hydroper-
oxide resistance gene, ohr  (BCAM2753; Table 4) was
observed; this gene is known to be inducible by organic
peroxides [27] and to lesser extent by hydrogen peroxide
[28]. The second, slightly upregulated (2.2-fold) gene was
osmC (BCAL1766) that is also involved in defence against
oxidative stress [29].
The significant fold change in ohr expression suggested
that the induction of bacterial defence against ROS had
taken place, despite the fact that antioxidant encoding
genes [30] such as catalases (KatA and KatB), alkyl
hydroperoxide reductases (AhpC) and superoxide dis-
mutases (SodB and SodC), remained unaffected. To vali-
date the oxidative stress model formulated from the
microarray results, we performed further set of growth
experiments where B. cenocepacia J2315 cells were exposed
to sub-inhibitory levels of ROS (0.1% H2O2, 0.15% H2O2
and 0.002% tert-butyl hydroperoxide, a member of
organic hydroperoxides family). After RNA extraction, the
expression of ohr was then determined by RQ-PCR analy-
sis. The quantitative PCR results showed activation of ohr
in all test conditions, with the greatest response occurring
after exposure to H2O2 (Table 3), confirming the involve-
ment of ohr in mediating B. cenocepacia response to both
inorganic and organic forms of peroxides.
In addition to oxidative stress, infecting bacteria are
threatened by nitrosative stress coming from reactive
nitrogen species (RNS) such as nitric oxide radicals [31].
Although the mechanisms of enzymatic detoxification of
RNS are not as well characterized as the responses to ROS,
there is evidence that nitrite reductase enzyme may play
an important role [32]. Growth of B. cenocepacia in spu-
tum triggered very high expression of a nitrite/sulfite
reductase (BCAM1676; 20-fold) and its neighbouring
gene of unknown function (BCAM1677; 26-fold); a
potential role in infection for these two genes has not
been previously implicated. Also since B. cepacia complex
bacteria are well known to be very resistant to the neu-
trophil-mediated non-oxidative killing [33], the signifi-
cant upregulation of this nitrite/sulfite reductase pathway
may form the basis for their resistant phenotype.
Motility and adherence
B. cenocepacia are motile bacteria and possess one or more
flagella. In addition to mediating motility, the flagellum
may also act as an adhesin establishing a primary contact
with epithelial cells and playing a central role in establish-
ing the initial phases of host colonization [2]. B. cenocepa-
cia flagellum-mediated motility has also been shown to
enable it to invade host cells [34]. Over 40 genes, which
are distributed in several discrete clusters across the
genome and whose expression is arranged hierarchically,
contribute to the synthesis and assembly of the whole
flagellum.
Growth in sputum increased the expression of flagellar
structural genes (basal body MS-ring gene fliF; BCAL0525,
main flagellin chaperone gene fliS; BCAL0527, C-ring
gene  fliM; BCAL3506, hook-protein gene flgE;
BCAM0987; Table 4) as well as of one regulatory gene
(flhD; BCAL0124; Table 4). In two of the three patients
sputa examined, the major structural component, flagel-
lin (fliC; BCAL0114), was also found to be overexpressed
(with a 3-fold change in expression), however, the gene
was excluded from the final gene list because of the filter-
ing criteria that was applied across the entire dataset (see
Methods and Materials). Only one gene associated with
assembly of the flagellum was downregulated, fliO
(BCAL3504; Table 4); this gene is thought to be part of the
type III secretion system involved in the flagellar protein
export [35]. Why this particular gene exhibited lower
expression was not clear since other components of the
secretion system (i.e., fliH; BCAL0523, fliI; BCAL0522,
fliP; BCAL3503, fliQ; BCAL3502 and fliR; BCAL3501) did
not change their level of expression and the whole system
is believed to be necessary for transmembrane transport of
the synthesized flagellar components.
The changes in expression of adhesins were not limited to
flagellum, but also occurred in pili encoding genes. The
gene for structural units of recently described type IV pili
(flp; BCAS0299) [36] was found to be significantly upreg-
ulated (Table 4), although its leader peptidase exhibited
slightly decreased expression (BCAS0301; Table 4). Other
fimbriae affected by growth in sputum were the cable pili
which are exclusively expressed by strains of ET12 clonal
complex [37]. Nearly the entire cable pilus gene cluster
was significantly downregulated (cblS, BCAM2758; cblD,
BCAM2759; cblA, BCAM2761 and cblB, BCAM2762; Table
4) suggesting that during growth in CF sputum these sur-
face structures are not essential. In contrast, the cable pilus
adherence-mediating 22 kDa adhesion protein (adhA;
BCAM2143) [38], was found to be upregulated (Table 4).
Secretion
Bacteria use various secretory pathways to translocate exo-
products and proteins that form their external cellular
structures through the membranes. Two of them, type II
and type III secretion systems, exhibited altered expres-
sion in their component genes during the growth of B.
cenocepacia in sputum. The majority of type II secretion
genes were downregulated (BCAL3515, BCAL3521-3522;
Table 4) with the only exception was being upregulation
of BCAL3517 (Table 4). Two components of the B. cenoce-
pacia type III secretion system showed increased expres-BMC Infectious Diseases 2008, 8:121 http://www.biomedcentral.com/1471-2334/8/121
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sion (BCAM2040 and BCAM2042; Table 4). Type II
secretion systems have an evolutionary relationship with
the Type IV pilus [39], a component of which, BCAS0299,
was also upregulated (Table 4); Type III secretion systems
share homology with the flagella gene systems [40] which
were also upregulated in B. cenocepacia. The upregulation
of all the latter systems suggest that there may be a com-
mon regulatory mechanism present that controls their
transcription in B. cenocepacia.
Many bacterial exoproducts are known to play important
roles in infection and two proteases with altered gene
expression were notable in the context of B. cenocepacia
virulence in CF. The ZmpA metalloprotease is a well char-
acterised Bcc virulence factor which is known to play a
role during infection when examined rat chronic lung
infection model [41]. The gene encoding ZmpA,
BCAS0409, was upregulated 6-fold (Table 4) during
growth in sputum, corroborating the data from animal
studies that this is a core B. cenocepacia virulence factor. A
second, as yet uncharacterised protease, BCAL0849 was
also upregulated 3-fold (Table 4) suggesting it may also
play a role during growth in sputum. However, no altera-
tion in expression of ZmpB (BCAM2307), another well
characterised Bcc protease [42], was detected.
Gene clusters
In addition to functional classification, we identified sev-
eral clusters of genes where CDSs in close vicinity to each
other demonstrated an altered expression (Table 4). These
putative operons contained two or more genes with
remarkably high values transcriptional fold change (2 to
90 fold) which further underlined a very likely co-regula-
tion of their transcription. Two under expressed gene clus-
ters represented well defined operons: the cable pilus
operon (as described above; Table 4) and a cluster of ure-
ase structural protein genes (significantly downregulated
were BCAL3104-6 and BCAL3109; Table 4). The remain-
ing putatively co-regulated gene clusters comprised
groups of genes that were either hypothetical or their
functional classifications were rather general in nature.
Out of these groups, a complex of nine consecutive hypo-
thetical genes which all showed a 5–22 fold decrease in
expression (BCAM0066-0074) was interesting. A similar
cluster, also exhibiting coordinated expression of all genes
but this time significant upregulation, comprised genes
BCAM2749-2754 including the above mentioned
hydroperoxide resistance gene ohr  (Table 4). In the
absence of functional data on these genes the physiologi-
cal significance of these findings remain to be determined,
however, they do illustrate the ability of transcriptomic
analysis to reveal novel genes implicated in bacterial
pathogenesis.
Several pairs of upregulated genes were identified which
featured extreme changes in their expression. The highest
values in the dataset were detected for the pair BCAL1106-
1107 (cytochrome b and oxidoreductase; described
above, Table 4). Other pairs of high expression were
BCAL0269-0270 (oxidoreductase and ferric reductase;
Table 4) and BCAM1676-1677 (nitrite/sulphite reductase
and conserved hypothetical protein; Table 4).
A feature of the genomic content and evolution of Bur-
kholderia  bacteria is the presence of a large amount
(approximately 10%) of recently acquired DNA in the
form of genomic islands [2,12]. However, very few of the
differentially expressed CDSs were found to reside within
B. cenocepacia J2315 genomic islands. This suggested that
the factors necessary for pathoadaptation to cystic fibrosis
and early growth in sputum were more inherent B. cenoce-
pacia  traits and were not recently acquired via mobile
genetic elements. Only one island on the largest chromo-
some (designated BcenGI5; M. Holden, unpublished
data), contained significant number of differentially
expressed genes and this comprised a mixture of both up-
and down-regulated genes. Three of the upregulated CDSs
(BCAL1153, 1156, 1157) comprise part of a putative
hydroxybenzoate catabolism cluster, and includes a sali-
cylaldehyde dehydrogenase (BCAL1153), which catalyses
the conversion of salicylaldehyde to salicylate. Although it
appears that the salicylaldehyde dehydrogenase is part of
a horizontally acquired xenobiotic degradation pathway,
this enzyme may also have an additional role in the iron
metabolism of J2315 as discussed above. Seven genes
within the island were downregulated (BCAL1130, 1161–
1162, 1165–1166 and 1168–1169; Table 4) and were of
no known function. Transcriptomic analysis also demon-
strated that apart from downregulation of the quorum-
sensing regulator, cciIR (Table 4), no other gene on the
Cenocepacia Pathogenicity Island (cci) [43] was altered in
expression, suggesting that this island implicated in
chronic lung infection is not extensively involved in rapid
growth in CF sputum.
Discussion
Our study is the first full transcriptomic examination of a
CF pathogen from the B. cepacia complex. We have exten-
sively validated a custom microarray designed to the B.
cenocepacia J2315 genome, demonstrating that it produces
reproducible and quantitative results, as well as testing
and confirming the growth models of iron-restriction and
oxidative-stress formulated from the genomic expression
profiles. Understanding how infecting bacteria colonize,
grow and survive within sputum is fundamental to respi-
ratory pathogenesis in CF, and by examining six individu-
als in this study we also considerably expanded on
previous work examining the transcriptomic response of
the major CF pathogen, P. aeruginosa (a study where spu-BMC Infectious Diseases 2008, 8:121 http://www.biomedcentral.com/1471-2334/8/121
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tum from two CF patients was examined [13]). Many of
the gene pathways activated by B. cenocepacia in response
to growth in sputum correlated to known virulence mech-
anisms [2]; eg. antibiotic efflux and degradation, iron
metabolism, resistance to host defenses and motility),
however, what was particularly gratifying about the
microarray data was its ability to identify novel genes
involved in these functions and to highlight unexpected
trends in B. cenocepacia gene expression after growth in
sputum. As a method to examine virulence in an oppor-
tunistic pathogen with a large genome such as B. cenocepa-
cia, our choice to use a microarray-based experimental
strategy was fully validated.
The inability to clear Bcc bacteria from the CF lung with
antibiotics frequently leads to chronic respiratory infec-
tion and the emergence of pan-resistant strains that
require combination therapy to suppress [44]. Growth of
B. cenocepacia in sputum revealed that 8 efflux pumps sys-
tems (3 that were members of the RND family) were
altered in expression (4 up- and 4 down-regulated; Table
4). Thirteen putative multidrug efflux pumps of RND fam-
ily have been characterised in B. cenocepacia J2315
genome; four of them have been shown to be transcrip-
tionally active during the growth in Luria-Bertani
medium, although their mode of expression (constitutive
or regulated) was not elucidated [19]. Our transcriptomic
data indicated that three of these RND pumps are under
transcriptional regulation (BCAL1675, BCAL1813 and
BCAM1947; Table 4) and not constitutively expressed in
B. cenocepacia. These three RND systems and the five addi-
tional efflux transport systems highlighted by the microar-
ray analysis are worthy of further study in relation to their
role in growth and antibiotic resistance. Looking for
inhibitors of these systems may improve the efficacy of
current antibiotics as well as weaken the ability for B. cen-
ocepacia to grow in sputum.
The B. cenocepacia ceo efflux system [20] was not activated
in any of the sputum samples, an observation that corre-
lated to the lack chloramphenicol, trimethoprim or cipro-
floxacin therapy. The ceo pump is also known to actively
efflux salicylate [20], whose biosynthetic pathway was
upregulated in sputum along with several other iron-
acquisition systems. Nair et al. [20] hypothesized that
there was a redundancy in salicylate transport systems
since Bcc strains lacking a complete set of ceo genes were
detected in their study, an observation that appears to be
supported by the lack of ceo expression yet siderophore
overexpression seen in the microarray data. Candidate sal-
icylate transporters may constitute the other sputum-acti-
vated RND efflux pumps (BCAL1675 and BCAM1947;
Table 4).
It is also possible that the observed increase in RND pump
expression (see above) may have also been induced by
low iron concentrations rather than by presence of antibi-
otics per se. A link between iron, siderophore secretion
and RND pump activity has been described in P. aerugi-
nosa  where mutants lacking mexA  or mexB  RND efflux
pump encoding genes were not able to grow on iron-defi-
cient medium [45]. Factors involved in iron acquisition
such as siderophores and their uptake mechanism are
known to be important for B. cenocepacia virulence [21].
However, the microarray analysis also revealed poten-
tially important roles for a ferric reductase in iron uptake
and the frataxin-like cyaY gene in iron storage and the for-
mation of Fe-S clusters. A link between CyaY and Fe-S pro-
tein biosynthesis has been recently proposed for
prokaryotes [24]. Based on such evidence, we suggest that
Fe-S cluster may play a primary role in iron storage during
growth of B. cenocepacia in sputum.
Recently, Kohanski et al. [46] proposed a cascade of bio-
chemical events which take place in bacterial cells when
exposed to bactericidal antibiotics. The pathway, which is
characterized by production of hydroxyl radicals via Fen-
ton chemistry, may represent an ultimate killing mecha-
nism of bactericidal antibiotics. In the Kohanski model,
the formation of ROS occurs via oxidation of ferrous ions
whose key intracellular source is thought to be iron-sul-
phur clusters [46]. Our study revealed significant changes
in activity of several genes which may be pieces of the
same puzzle in B. cenocepacia and represent the bacterial
protective response against hydroxyl radicals: cyaY  (a
frataxin-like gene; BCAL0273), ohr (hydroperoxide resist-
ance gene; BCAM2753) and iron acquisition genes
(siderophores, salicylate biosynthesis and membrane fer-
ric reductase). Since CF patients are on constant antimi-
crobial therapy, the large amounts of residual antibiotics
in sputum may stimulate oxidation of free ferrous ions in
the Fenton reaction, hence triggering an imbalance in
intracellular iron distribution which results in the activa-
tion of the iron cycle genes we have observed in B. cenoce-
pacia.
In addition to identifying potentially new B. cenocepacia
virulence mechanisms, the transcriptomic analysis also
revealed interesting trends in the expression of known vir-
ulence factors. For example, the upregulation of flagellar
genes observed in B. cenocepacia contrasted markedly with
the results of P. aeruginosa transcriptomic analysis, where
the expression of flagella was repressed during the incuba-
tion in CF sputum [13]. While adaptation to a non-motile
phenotype is a well-characterised trait of P. aeruginosa dur-
ing chronic CF infection [47], this phenomenon has not
been observed in Bcc bacteria. The upregulation of B. cen-
ocepacia  flagellar apparatus genes suggests that motility
may allow this CF pathogen to maintain a more invasiveBMC Infectious Diseases 2008, 8:121 http://www.biomedcentral.com/1471-2334/8/121
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phenotype during infection. Maintaining motility may
also correlate to the fact that B. cenocepacia and other Bcc
bacteria retain their ability to cause a septic, invasive,
"cepacia syndrome" at any point during chronic CF infec-
tion [5,6].
Another example of an unexpected expression finding was
the lack of activation of the structural components of
cable pilus operon of B. cenocepacia J2315. Studies on a B.
cenocepacia cable pilus knockout mutant showed that it
was not altered in its capacity to bind lung epithelial cells
[48], which taken together with our transcriptomic data,
this suggests that the complete cable pilus may not be as
important colonization surface structure as initially pre-
sumed [37]. However, we did find that the pilus-associ-
ated adhesin gene, adhA [38], was activated in sputum
suggesting it is important for growth. In absence of cable
pilus expression this finding also indicates that the AdhA
adhesin may be incorporated onto other B. cenocepacia
surface components.
Quorum sensing, the bacterial cell-to-cell communication
system, controls many virulence genes functions in B. cen-
ocepacia [2,49,50]. We did not detect expression changes
in three of the characterized B. cenocepacia quorum sens-
ing genes (i.e. N-acylhomoserine lactone synthases cepI
and cciI, and a response regulator cepR [43,49]). This may
have due to the fact that B. cenocepacia was only allowed
to grow to mid-log phase prior to microarray analysis, and
quorum sensing activity only normally appears at later
stages of growth. Limited signs of quorum sensing activity
were apparent from the overexpression of polygalacturo-
nase gene (BCAS0196), the zmpA  metalloprotease and
motility-associated flagellar genes, which are all under its
control [2,49,50]. The only quorum sensing gene exhibit-
ing altered expression (a 2.5-fold under-expression) was
cciR (BCAM0240; Table 4) which encodes a quorum sens-
ing transcriptional regulator known to be an autorepres-
sor [49].
Conclusion
Studying opportunistic bacterial pathogens with large
genomes, poor genetic tractability and limited models of
infection is not straightforward. Our transcriptomic anal-
ysis of B. cenocepacia growth in a sputum-based model has
provided a detailed snapshot of components of the J2315
genome that may promote colonisation and early growth
in the CF lung. Transcriptomic analysis corroborated pre-
vious studies that had shown crucial roles for iron uptake
and proteases in B. cenocepacia virulence. It also demon-
strated that upregulation of efflux proteins and genes
involved in antimicrobial stress are important. However,
from the multiple genetic pathways encoding the latter
phenotypic traits, microarray analysis demonstrated that
previously uncharacterised B. cenocepacia genes such as a
transmembrane ferric reductase (BCAL0270), protease
(BCAL0849), organic hydroperoxide (BCAM2753), oxi-
doreductase (BCAL1107) and nitrite/sulfite reductase
(BCAM1676), are significantly upregulated in sputum. In
contrast to the pathogenesis of P. aeruginosa in CF lung
infection, the expression of genes for motility and flagellar
biosynthesis were upregulated, allowing B. cenocepacia to
maintain a potentially invasive phenotype characteristic
of cepacia syndrome. Virulence factors such as the struc-
tural cable pilus and genes on the cci were not upregulated
during sputum growth suggesting they do not play an
important role at the initial stage of infection we mod-
elled. Overall, our successful transcriptomic analysis has
revealed several new virulence B. cenocepacia virulence
mechanisms worthy of further study and provided a refer-
ence set of gene expression data for growth of this patho-
gen in CF sputum.
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